TRAW — Traws Pharma, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1130598 ·
Last close
$0.23
Market Cap
$3.59M
52W High
$3.23
52W Low
$0.22
ADV30
199,468
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -3,175,000 -3,054,000 11,470,000 5,016,000 9,779,000
Mar 2026 0 — -6,946,000 -7,107,000 8,156,000 3,133,000 13,467,000
Dec 2025 0 — -7,368,000 -7,443,000 10,617,000 3,820,000 11,246,000
Sep 2025 0 — -4,055,000 -3,962,000 12,443,000 6,420,000 7,898,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-16,849,000
Investing CF
$-2,585,000
Financing CF
$11,383,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.14
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-650,145,000
Inventory
—
Receivables
$3,454,000
ST Investments
—
EBIT TTM
$-21,544,000
Pretax Income TTM
$-21,566,000
Interest Exp TTM
—
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-21,397,000
Free Cash Flow
$-13,326,000
Enterprise Value
$3,656,318
Total Cash
$5,016,000
Total Debt
$0
Shares Out
15,368,277
Trailing EPS
$-1.83
Book Value
$0.11
ROE
-433.4%
ROA
-99.4%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,790,000 -17,875,000 9,170,000 10,617,000 11,246,000 -629,000 -18,185,000
Dec 2024 226,000 -24,910,000 -166,523,000 24,962,000 56,592,000 -31,630,000 -29,792,000
Dec 2023 226,000 -20,298,000 -18,948,000 22,683,000 12,011,000 10,672,000 -17,932,000
Dec 2022 226,000 -19,627,000 -18,964,000 39,372,000 11,063,000 28,309,000 -16,294,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-21,566,000
OpCashFlow TTM
—
Assets (Latest)
$11,470,000
Forward EPS
$-1.88

Peers — same industry

TickerNameMarket CapLastDaily %
PMHS Polomar Health Services, Inc. $3.55M $0.13 —
AZTR Azitra, Inc. $3.68M $0.61 —
NCNA NuCana plc $3.70M $0.89 —
XBIO Xenetic Biosciences, Inc. $3.77M $1.61 —
SXTC China SXT Pharmaceuticals, Inc. $3.78M $2.86 —

News headlines (Yahoo Finance, 1h cache)

Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID®
2026-11-12 12:00 · Yahoo
Traws Pharma shares rise after Q2 loss comes in better than expected
2026-08-17 12:31 · Yahoo
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
2026-08-14 20:30 · Yahoo
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
2026-06-22 11:00 · Yahoo
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
2026-04-20 13:55 · Yahoo
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
2026-04-15 20:01 · Yahoo
Traws Pharma Provides Regulatory Update on Influenza Program
2026-06-12 21:30 · Yahoo
Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ...
2026-04-16 07:01 · Yahoo
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study
2026-06-15 10:26 · Yahoo
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
2026-05-08 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.